LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Home・Akciju saraksts・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Slēgts

SektorsVeselības aprūpe

28.23 -0.6

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.68

Max

28.64

Galvenie mērījumi
By Trading Economics
Ienākumi	-187M -136M
Pārdošana	4.3M 244M
P/E Sektora vidējais	9.117 66.845
EPS	1.08
Peļņas marža	-55.871
Darbinieki	293
EBITDA	-22M 52M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+45.91% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	117M 1.7B
Iepriekšējā atvēršanas cena	28.83
Iepriekšējā slēgšanas cena	28.23

Ziņu noskaņojums

By Acuity

38%

62%

123 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

29.8 / N/A Atbalsts un pretestība

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. marts 23:01 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

2026. g. 5. marts 21:54 UTC

Peļņas

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

2026. g. 5. marts 21:35 UTC

Galvenie tirgus virzītāji

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

2026. g. 6. marts 00:00 UTC

Galvenie ziņu notikumi

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

2026. g. 5. marts 23:46 UTC

Tirgus saruna

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

2026. g. 5. marts 23:33 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 5. marts 23:27 UTC

Tirgus saruna

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

2026. g. 5. marts 22:54 UTC

Tirgus saruna

Peļņas

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

2026. g. 5. marts 22:50 UTC

Tirgus saruna

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

2026. g. 5. marts 22:48 UTC

Peļņas

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026. g. 5. marts 22:46 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

2026. g. 5. marts 22:44 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. marts 21:35 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:32 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:26 UTC

Peļņas

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

2026. g. 5. marts 21:24 UTC

Peļņas

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

2026. g. 5. marts 21:23 UTC

Peļņas

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

2026. g. 5. marts 21:22 UTC

Peļņas

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco February Digitally-Enabled Sales Rose 21.8% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco Total Co Comparable Sales for February Rose 7.9% >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Costco February Net Sales Were $21.69 B >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:20 UTC

Peļņas

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:19 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Same-Store Sales Up 7.4% >COST

2026. g. 5. marts 21:15 UTC

Peļņas

Costco 2Q EPS $4.58 >COST

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

45.91% augšup

Prognoze 12 mēnešiem

Vidējais 41.25 USD 45.91%

Augstākais 62 USD

Zemākais 25 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

123 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.